Radiotherapy for Breast Cancer May Lower Short-Term Alzheimer’s Risk
Recent studies suggest that radiotherapy for breast cancer may reduce short-term risk of Alzheimer’s, opening new avenues in cognitive health research.
Radiotherapy for breast cancer linked to lower Alzheimer’s risk
Radiotherapy, a common treatment for breast cancer, may offer short-term protection against Alzheimer’s disease, according to recent research. A study led by Samsung Medical Center in South Korea analyzed data from nearly 70,000 breast cancer survivors, finding that those treated with radiation had an 8% lower risk of developing Alzheimer’s compared to women without cancer. The protective effect was most prominent shortly after treatment but seemed to diminish over time.
The findings, published in JAMA Network Open, suggest that radiation therapy might influence neuroprotective mechanisms, potentially reducing inflammation and neurodegeneration pathways. Experts emphasize that while these results are promising, longer-term studies are needed to fully understand the relationship between cancer treatments and Alzheimer’s risk.
This research opens new avenues for exploring how certain cancer therapies could impact cognitive health, highlighting the importance of personalized treatment approaches and the need for further investigation into long-term effects.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Respite Care Accessibility Significantly Increases Likelihood of Dying at Home for Palliative Patients
A landmark study reveals that access to respite care nearly triples the likelihood of palliative patients dying at home, promoting better quality end-of-life experiences.
Strategic Guidelines for Data Transformation to Promote AI Innovation in Primary Care
A new report outlines key strategies for transforming healthcare data to advance AI and machine learning in primary care, emphasizing collaboration, infrastructure, and targeted use cases.
FDA Approves Ajovy for Migraine Prevention in Children and Adolescents
The FDA has approved Ajovy, a CGRP antagonist, for preventing episodic migraines in children and adolescents aged 6 to 17, offering a new targeted treatment option for young patients. that can help reduce migraine attacks and improve quality of life.
